Dohn M N, Frame P T, Baughman R P, Lafon S W, Smulian A G, Caldwell P, Rogers M D
University of Cincinnati Medical Center, Ohio 45267-0564.
J Protozool. 1991 Nov-Dec;38(6):220S-221S.
Pneumocystis carinii pneumonia continues to be a cause of morbidity and mortality in AIDS patients. Current therapies have a high rate of toxicity and failure. Compound 566C80 is a 1-4,hydroxynaphthoquinone with potent antiprotozoal activity which shows good efficacy and safety in 21-day treatment trials of P. carinii pneumonia (PCP) in AIDS patients. Because there is a generally high recurrence rate after treatment of PCP and there may be a possible advantage in decreasing the P. carinii burden in the lung with extended anti-Pneumocystis therapy, we performed an open label-trial of the safety and efficacy of 42-day therapy with 566C80 for PCP in AIDS patients. Ten patients were enrolled and one was lost to follow-up. Eight of the remaining nine patients successfully completed 42 days of therapy with minimal toxicity. This trial suggests that 566C80 for 42 days can be an effective, safe, and well-tolerated oral therapy for PCP in AIDS patients.
卡氏肺孢子虫肺炎仍然是艾滋病患者发病和死亡的一个原因。目前的治疗方法毒性高且失败率高。化合物566C80是一种具有强大抗原生动物活性的1,4-羟基萘醌，在艾滋病患者卡氏肺孢子虫肺炎（PCP）的21天治疗试验中显示出良好的疗效和安全性。由于PCP治疗后复发率普遍较高，延长抗肺孢子虫治疗可能在降低肺部卡氏肺孢子虫负荷方面具有优势，我们开展了一项开放性试验，研究566C80对艾滋病患者PCP进行42天治疗的安全性和疗效。招募了10名患者，1名失访。其余9名患者中的8名成功完成了42天的治疗，毒性极小。该试验表明，566C80治疗42天对艾滋病患者的PCP可能是一种有效、安全且耐受性良好的口服治疗方法。
